Expanded Program On Immunization

Expanded Program on Immunization

Background and Definition

Expanded Program on Immunization (EPI), established in 1987, aimes at guaranteeing the right of every child in Lebanon, regardless of social status or parent's education level, on immunization and protection from diseases that have available effective and safe vaccines. In order to ensure that, the Ministry of Public Health guarantees the provision of vaccines in 700 health care centers, public and social, in collaboration with the private sector and with the conitnuous awareness of care givers about the importance of immunization. The program provides further special attention to chidlren residing in remote and underprivileged areas through quality outreach activities.

EPI ِAims at:

Elevating routine vaccination coverage per district to above 95%.
Preserving Lebanon as polio-free, considering the continuous influx of Syrian refugees and in preparation to the eradication of polio in the region and worldwide.
Eradicating Measles and Rubella by the end of year 2018.

EPI Activities:

Continuous training and capacity building throughout the year for health care workers on routine vaccination management and implementation in all districs.
Continuous work to keep Lebanon certified polio-free
Implementation of the RED STRATEGY to reach every child, which includes:
1. Data on the immunization coverage for children under one year of age
2. Data on immunization coverage in Lebanon
3. Identification of the number of drop-outs and planning to ensure their vaccination per district accordingly
Celebrating World Immunization Week and planning awareness sessions over Lebanon about routine vaccination
Conducting National and Mop-Up Immunization campaigns annually, including vaccination against Measles, Rubella, and Mumps
Conducting regular visits by the self-assessment team to follow on the quality of vaccination delivery service
Continuous collaboration with UNICEFand WHO to follow-up on updates related to immunization worldwide and ensuring implementation in Lebanon considering national and international commitments
Continuous collaboration with the private sector (General Practictioners and Pediatricians) to ensure vaccination for all children in Lebanon, particularly during immunization campaigns and routine immunization.

...

193

All

ATC	Name	B/G	Ingredients	Dosage	Form	Price
B05CX01	SERUFLEX DEXTROSE 5% INJECTION USP	G	Glucose - 5%	5%	Injectable solution	158,587 L.L
J06BA02	HIZENTRA 4G	BioHuman	Immunoglobulin human - 4g/20ml	20%	Injectable solution	34,237,996 L.L
M09AX01	HYALGAN	B	Hyaluronic acid (sodium) - 20mg/2ml	20mg/2ml	Injectable solution	3,407,985 L.L
N03AB02	? PHENYTOIN SODIUM 5% USP	G	Phenytoin (sodium) - 250mg/5ml	5ml	Injectable solution	276,448 L.L
S01LA04	LUCENTIS	BioTech	Ranibizumab - 10mg/ml	10mg/ml	Injectable solution	51,255,093 L.L
B05CX01	SERUFLEX DEXTROSE 5% INJECTION, USP	G	Glucose - 5%	5%	Injectable solution	171,228 L.L
J06BA02	IG VENA	BioHuman	Human normal immunoglobulin - 1g/20ml	1g/20ml	Injectable solution	7,474,948 L.L
S01LA05	EYLEA	BioTech	Aflibercept - 40mg/ml	40mg/ml	Injectable solution	65,161,855 L.L
D11AH05	DUPIXENT	BioTech	Dupilumab - 300mg	300mg	Injectable solution	L.L
B05CX01	SERUFLEX DEXTROSE 5% INJECTION, USP	G	Glucose - 5%	5%	Injectable solution	193,062 L.L
S01LA05	EYLEA	BioTech	Aflibercept - 8mg/0.07ml	114.3mg/ml	Injectable solution	78,332,038 L.L
B05CX01	SOLUFLEX DEXTROSE 5% INJECTION USP	G	Glucose - 5%	5%	Injectable solution	186,167 L.L
J06BB01	RHOPHYLAC 300	BioHuman	Human anti-D (rh) immunoglobulin - 300mcg/2ml	300mcg/2ml	Injectable solution	5,939,784 L.L
M01AB05	ALMIRAL	G	Diclofenac sodium - 75mg/3ml	75mg/3ml	Injectable solution	415,247 L.L
S01LA06	BEOVU	BioTech	Brolucizumab - 120mg/ml	120mg/ml	Injectable solution	42,752,178 L.L
B05CX01	SOLUFLEX DEXTROSE 5% INJECTION USP	G	Glucose - 5%	5%	Injectable solution	186,167 L.L
J06BB01	RHESONATIV	BioHuman	Human anti-D (rh) immunoglobulin - 625IU/ml	625IU/ml	Injectable solution	12,281,758 L.L
M01AB05	CLOFEN	G	Diclofenac sodium - 75mg/3ml	75mg/3ml	Injectable solution	299,677 L.L
S01LA09	VABYSMO	B	Faricimab - 6mg/0.05ml	6mg/0.05ml	Injectable solution	54,991,170 L.L
B05CX01	SOLUFLEX DEXTROSE 5% INJECTION, USP	G	Glucose - 5%	5%	Injectable solution	205,703 L.L
J06BB02	TETAGAM P	BioHuman	Human Tetanus Immunoglobulin - 250IU/ml	250IU/ml	Injectable solution	3,075,475 L.L
M01AB05	DICLOCELL	G	Diclofenac sodium - 75mg/3ml	75mg/3ml	Injectable solution	945,809 L.L
B02BX06	HEMLIBRA	BioTech	Emicizumab - 60mg/0.4ml	60mg/0.4ml	Injectable solution	441,042,377 L.L
B05CX01	SOLUFLEX DEXTROSE 5% INJECTION, USP	G	Glucose - 5%	5%	Injectable solution	221,792 L.L
J06BB02	TETANUS GAMMA	BioHuman	Human Tetanus Immunoglobulin - 250IU/ml	250IU/ml	Injectable solution	3,077,399 L.L
M01AB05	DICLO-DENK 75 INJECTION	G	Diclofenac sodium - 75mg/3ml	75mg/3ml	Injectable solution	716,268 L.L
N01AH01	FENTANYL PANPHARMA	G	Fentanyl - 0.1mg/2ml	0.1mg/2ml	Injectable solution	1,101,951 L.L
B02BX06	HEMLIBRA	BioTech	Emicizumab - 30mg/ml	30mg/ml	Injectable solution	224,585,721 L.L
B05CX01	SOLUFLEX DEXTROSE 5% INJECTION, USP	G	Glucose - 5%	5%	Injectable solution	185,018 L.L
J06BB04	IMMUNOGLOBULINE HUMAINE DE L'HEPATITE B LFB	BioHuman	Hepatitis B immunoglobulin (human) - 100UI/ml	100UI/ml	Injectable solution	6,853,730 L.L

...

193